In clinical practice, elevated intraocular pressure (IOP) is commonly observed in cases of glaucoma or ocular hypertension. Glaucoma has a global impact on 60 million individuals, with 8.4 million experiencing complete blindness in both eyes as a result of this persistent condition. Methods for decreasing intraocular pressure (IOP) involve the use of pharmaceutical substances, laser therapies, and surgical procedures, which can be either invasive or non-invasive. Over the past two decades, there have been substantial alterations in all of these tactics. Increased intraocular pressure (IOP) is the primary and most influential risk factor for the onset and advancement of glaucoma. As of now, it is the only risk factor that has been definitively proven to be adjustable. Excessively elevated intraocular pressure (IOP) leads to fast and significant deterioration of vision, accompanied by severe impairment of the optic nerve. Ocular hypertension refers to a long-term, slight increase in intraocular pressure (IOP), which can cause gradual alterations in visual function and the appearance of the optic nerve.